back

Loncastuximab tesirine (indication: diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), for patients with ≥ 2 prior therapies)

 

Subject:

  • Active Substance: Loncastuximab tesirine
  • Name: Zynlonta®
  • Therapeutic area: Diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL)
  • Pharmaceutical company: Swedish Orphan Biovitrum GmbH

 

Time table:

  • Start: 15.05.2023
  • Publication of assessment: 15.08.2023
  • End of public hearing: 05.09.2023
  • Final decision by G-BA: beginning of November 2023

 

Comparative therapy:

  1. Adults who are eligible for high-dose therapy: therapy at the physcian's discretion choosing from
    - tisagenlecleucel,
    - axicabtagen-ciloleucel,
    - induction therapy with MINE (mesna, ifosfamide, mitoxantrone, etoposide) followed by high-dose therapy with autologous stem cell transplantation in case of response to induction therapy,
    - induction therapy with MINE (mesna, ifosfamide, mitoxantrone, etoposide) followed by high-dose therapy with allogeneic stem cell transplantation in case of response to induction therapy
     

  2. Adults who are not eligible for high-dose therapy: therapy at the physcian's discretion choosing from
    - CEOP (cyclophosphamide, etoposide, vincristine, prednisone),
    - dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, prednisone),
    - polatuzumab vedotin + bendamustine + rituximab,
    - tafasitamab + lenalidomide,
    - monotherapy pixantrone,
    - radiation
    - best supportive care